Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


TiGenix Reports Positive Interim Safety Results of Phase IIa Rheumatoid Arthritis Study with Allogeneic Adult Stem Cells "Cx611" 

 

 

December 19, 2012 - (TiGenix) - "TiGenix, the European leader in cell therapy, announced today positive interim safety results of its Phase IIa study of Cx611 in rheumatoid arthritis (RA). Cx611 is an intravenously injected suspension of expanded allogeneic adult stem cells derived from human adipose (fat) tissue. The Phase IIa clinical trial is a 53-subject, multicenter, placebo-controlled study in 3 cohorts with different dosing regimens, designed to assess safety, feasibility, tolerance, and optimal dosing." Read Full Press Release

 

Posted on 9-Jan-13 by Toto, Brent
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: